Inside Botox's margin of error, the next generation of gene editing tools, healing healthcare with startups and other interesting reads from the past week.

General

Wanted: 11 million health professionals to save Africa from "disaster". Link

Novo Nordisk warns diabetes costs threaten to overwhelm healthcare. Link

Science 37 conducts industry's first virtual clinical trial. Link

Amazon is making moves to get into the drug distribution business. Link

The world's best-selling drug may just keep on growing. Link

Glaxo sees profit rise in the third quarter amid strong first year for CEO Walmsley. Link

A second straight victory for Johnson & Johnson as record $417 million verdict reversed. Link

Wonderful long read: Inside Botox's margin of error. Link

Digital Health

FDA has approved a faster way to check for allergies. Link

The ‘Uber for birth control’ expands in conservative states. Link

FDA approves app-enabled heart monitor. Link

Research

Millions die of pneumonia each year — a vaccine could change that. Link

The next generation of gene editing tools. Link

Scientists identify new gene variations linked to breast cancer. Link

Blood-thinning drugs 'can reduce risk of dementia by up to 48%'. Link

Perspectives and Opinions

Patients need rest, not antibiotics, say health officials. Link

Here’s why vaccines are so crucial. Link

Healing healthcare with startups. Link

Interesting

The Body Brokers — free cremation for donating your loved one's body "to advance medical studies". Link

U.S. scientists recreate human brain cells with computers. Link

Startups of the Week

Spinal Singularity

Spinal Singularity is advancing the Connected Catheter, a fully internal, extended-use catheter system for adult males with chronic Lower Urinary Tract Dysfunction.

CorFlow Therapeutics

CorFlow is a Switzerland-based company that is developing proprietary technologies for diagnosis and treatment of microvascular obstructions (MVO). Its technologies aim to enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients

Appili Therapeutics

Appili Therapeutics is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline.

Y-mAbs Therapeutics

YmAbs is a clinical-stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. Its lead antibody programs target GD2 and B7-H3.